國家衛生研究院 NHRI:Item 3990099045/4632
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12500/13673 (91%)
造訪人次 : 2439775      線上人數 : 217
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4632


    題名: Cost-minimization analysis of capecitabine for advanced gastric cancer in Taiwan
    作者: Chang, CS;Chao, Y;Chen, JS;Chen, LT;Chung, CH;Hsieh, RK;Hwang, WS;Yang, L;De Reyder, F
    貢獻者: National Institute of Cancer Research
    摘要: OBJECTIVE: Gastric cancer is the fifth most prevalent cancer and the fifth cause of cancer-related mortality in Taiwan. The objective of this study was to access the cost-effectiveness of capecitabine plus cisplatin (XP) vs. intravenous 5-fluorouracil plus cisplatin (FP) for the treatment of advanced and metastatic gastric cancer (AGC) in Taiwan, from a payer’s (Bureau of National Health Insurance [BNHI]) perspective. METHODS: A cost-minimization analysis (CMA) was conducted by applying clinical outcomes and medical resource utilization (MRU) derived from the phase III ML17032 study. Direct medical costs associated with trial-based MRU were based on Taiwan’s National Health Insurance fee schedule for 2007. Costs associated with intravenous chemotherapy administration and adverse event (AE) management were estimated by an expert panel survey conducted among 12 oncologists. One-way sensitivity analyses were performed on key model parameters by varying the input values by 20%. RESULTS: A trend toward superior progression-free survival was observed in the XP arm (median 5.6 months for XP vs. 5.0 for FP). Patients in the XP arm received 5.2 cycles of therapy vs. 4.6 cycles of FP. Compared to FP, administration of XP required fewer consults per patient (5.2 for XP vs. 22.8 for FP). Chemotherapy drug cost was higher (USD$1712) in the XP arm; however, these cost increments were offset by differences of chemotherapy administration costs (USD$4376) between two arms. AE profiles were similar and the cost associated with grade 3/4 AE management were slightly lower (USD $30) in the XP arm. Overall, XP was associated with a cost saving of USD$2691(NTD$87,351). XP remained cost-saving under one-way sensitivity analyses. CONCLUSION: From the Taiwan BNHI perspective, this CMA demonstrates that replacing FP by XP for the treatment of AGC would not only save direct medical costs but also improve health outcomes in Taiwan.
    日期: 2008-05
    關聯: Value in Health. 2008 May-Jun;11(3):A64-A65.
    Link to: http://dx.doi.org/10.1111/j.1524-4733.2008.00383_2.x
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1098-3015&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000255945400213
    顯示於類別:[陳立宗] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000255945400213.pdf74KbAdobe PDF240檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋